Belgian pharmaceutical leader UCB has unveiled a monumental $2 billion investment plan to construct a state-of-the-art drug manufacturing plant in suburban Atlanta, Georgia. This strategic move is set to generate around 330 new employment opportunities and significantly bolster the company's footprint in the critical United States healthcare market.
Major Expansion in Gwinnett County
The new biologics facility will be situated in Gwinnett County, on the eastern periphery of the Atlanta metropolitan area. Company executives have highlighted that the location was chosen for its proximity to leading academic institutions, including Georgia Tech in Atlanta and the University of Georgia in Athens. Both universities have been actively fostering biomedical research and manufacturing ecosystems, making the region an attractive hub for pharmaceutical innovation.
The plant is planned for a nascent research park that local boosters envision could one day compete with the renowned Research Triangle Park in North Carolina. This development represents a significant economic win for the region, aligning with broader efforts to cultivate advanced manufacturing and life sciences sectors.
Driving Growth and Meeting Demand
"This decision reflects our confidence in UCB's long-term growth and our deep-rooted commitment to the United States," stated UCB CEO Jean-Christophe Tellier in an official announcement. The investment is a direct response to the company's rapid expansion and increasing demand for its specialized treatments.
UCB has experienced remarkable financial performance, with revenues surging 26% to nearly $9 billion in 2025. Profits saw an even more dramatic increase, jumping 46% to $1.81 billion. The new facility is specifically designed to ensure reliable and timely access to vital treatments for patients, particularly for neurological and autoimmune diseases—the company's current therapeutic focus.
Jacques Marbehant, a key UCB executive, emphasized in a blog post that "The new biologics facility in Gwinnett County, Georgia, is designed to meet increasing demand and ensure patients receive reliable, timely access to vital treatments."
Substantial Incentives and High-Paying Jobs
Gwinnett County officials have committed to providing $174 million in incentives to secure the project. This package includes substantial property tax breaks, fee waivers, and targeted infrastructure improvements. The jobs created are expected to pay an average annual salary exceeding $72,000, offering significant economic benefits to the local community.
Furthermore, UCB could qualify for additional state-level benefits, including millions of dollars in income tax credits, a sales tax waiver on equipment purchases, and state-funded job training programs. These incentives underscore the competitive efforts by Georgia to attract high-value pharmaceutical manufacturing.
Strategic Focus and Historical Context
UCB, historically known for developing popular antihistamines like Zyrtec and Xyzal, has strategically pivoted towards complex therapies for neurological and autoimmune conditions. Its current blockbuster drug, Bimzelx, is used to treat conditions such as psoriasis and inflammatory arthritis, representing the cutting edge of its research and development efforts.
The announcement follows a June declaration by the company of its intent to build a new U.S. factory and increase its reliance on U.S.-based contract manufacturers. UCB already employs approximately 2,000 people across its existing U.S. operations, with its American headquarters located in Smyrna, another Atlanta suburb.
Design and construction of the sprawling new facility are projected to take between six and seven years, indicating the scale and complexity of the project. This long-term commitment highlights UCB's strategic view of the United States as a cornerstone market for its future growth and innovation in the global pharmaceutical landscape.
